Fenharmane

Fenharmane

SCHEMBL9696484

Cl.c1ccc(CC2NCCc3c2[nH]c2ccccc32)cc1

nearest known ligand 0.97

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Fenharmane. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
GRIN2B known ✓ Q13224 1/20 0.97
HTR2A known ✓ P28223 6/20 0.75
HTR2C known ✓ P28335 2/20 0.75
HTR7 known ✓ P34969 7/20 0.73
CHRM4 known ✓ P08173 5/20 0.73
DRD2 known ✓ P14416 2/20 0.69
CTSK P43235 1/20 0.62
CYP3A4 P08684 1/20 0.59
CYP2D6 P10635 1/20 0.59
CYP2C19 P33261 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Fenharmane SCHEMBL9695673 0.99 GRIN2B (1.00) GRIN2BHTR2AHTR2CHTR7CHRM4
SCHEMBL18087743 0.85 GRIN2B (0.76) GRIN2BHTR2AHTR2CHTR7CHRM4
SCHEMBL8402972 0.83 HTR2A (1.00) GRIN2BHTR2AHTR2CHTR7CHRM4
SCHEMBL8402971 0.83 HTR2A (0.74) GRIN2BHTR2AHTR2CHTR7CHRM4
Hydrochloric Acid SCHEMBL9393283 0.82 HTR7 (0.68) GRIN2BHTR2AHTR2CHTR7CHRM4
SCHEMBL5532807 0.81 GRIN2B (0.70) GRIN2BHTR2AHTR2CHTR7CHRM4
SCHEMBL8322968 0.81 GRIN2B (0.70) GRIN2BHTR2AHTR2CHTR7CHRM4
SCHEMBL10924004 0.81 GRIN2B (0.70) GRIN2BHTR2AHTR2CHTR7CHRM4
SCHEMBL21883968 0.81 GRIN2B (0.70) GRIN2BHTR2AHTR2CHTR7CHRM4
SCHEMBL29756361 0.81 GRIN2B (0.70) GRIN2BHTR2AHTR2CHTR7CHRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240307359-A1 METHOD OF SCREENING FOR AGENTS FOR DIFFERENTIATING STEM CELLS MINERVA BIOTECHNOLOGIES CORP (US) 2024-09-19 US disclosed
US-11931347-B2 Method of screening for agents for differentiating stem cells MINERVA BIOTECHNOLOGIES CORPORATION (US) 2024-03-19 US disclosed
CN-113527289-A Method for screening agent for differentiating stem cells 米纳瓦生物技术公司 2021-10-22 CN disclosed
US-20180263964-A1 METHOD OF SCREENING FOR AGENTS FOR DIFFERENTIATING STEM CELLS MINERVA BIOTECHNOLOGIES CORPORATION (US) 2018-09-20 US disclosed
EP-3352566-A2 METHOD OF SCREENING FOR AGENTS FOR DIFFERENTIATING STEM CELLS Minerva Biotechnologies Corporation (US) 2018-08-01 EP disclosed
WO-2017053886-A2 METHOD OF SCREENING FOR AGENTS FOR DIFFERENTIATING STEM CELLS MINERVA BIOTECHNOLOGIES CORPORATION (US) 2017-03-30 WO disclosed
US-5169852-A Anorexigenic agents NEUREX CORPORATION (US) 1992-12-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180263964-A1 METHOD OF SCREENING FOR AGENTS FOR DIFFERENTIATING STEM CELLS MCL1, CRABP2, MYADM GRIN2B 3817/4885HTR2A 4495/4885HTR2C 4518/4885
US-11931347-B2 Method of screening for agents for differentiating stem cells MCL1, CRABP2, MYADM GRIN2B 3817/4885HTR2A 4495/4885HTR2C 4518/4885
US-20240307359-A1 METHOD OF SCREENING FOR AGENTS FOR DIFFERENTIATING STEM CELLS MCL1, CRABP2, MYADM GRIN2B 3817/4885HTR2A 4495/4885HTR2C 4518/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.